Nihon Chouzai Reports Fiscal Year 2025 Financial Results with Plans for Recovery

Nihon Chouzai Co ( (JP:3341) ) has issued an update.

Nihon Chouzai Co., Ltd. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing a 5.9% increase in net sales to 360,512 million yen. However, the company experienced declines in EBITDA, operating profit, and ordinary profit, with a significant drop in profit attributable to owners of the parent by 45.5%. Despite these challenges, the company maintained its dividend per share at 25 yen, reflecting a commitment to shareholder returns. The financial outlook for the next fiscal year anticipates modest growth in net sales and a substantial increase in profit attributable to owners of the parent by 151.6%, indicating a potential recovery and strategic adjustments to improve profitability.

More about Nihon Chouzai Co

Nihon Chouzai Co., Ltd. operates in the healthcare industry, primarily focusing on pharmaceutical services and products. The company is listed on the Tokyo Stock Exchange and is known for its contributions to the medical and pharmaceutical sectors in Japan.

YTD Price Performance: 0.25%

Technical Sentiment Signal: Strong Sell

Current Market Cap: $602.7M

For a thorough assessment of 3341 stock, go to TipRanks’ Stock Analysis page.